Does an early invasive strategy reduce major cardiac events in patients with unstable angina and NSTEMI treated with tirofiban?
An early invasive strategy significantly reduces major cardiac events in patients with unstable angina and NSTEMI receiving glycoprotein IIb/IIIa inhibition.
In patients with unstable angina and myocardial infarction without ST-segment elevation who were treated with the glycoprotein IIb/IIIa inhibitor tirofiban, the use of an early invasive strategy significantly reduced the incidence of major cardiac events. These data support a policy involving broader use of the early inhibition of glycoprotein IIb/IIIa in combination with an early invasive strategy in such patients.
Building similarity graph...
Analyzing shared references across papers
Loading...
New England Journal of Medicine
Brigham and Women's Hospital
Emory University
Baylor College of Medicine
Add This Paper to Your Research Feed
Any time a new paper drops it will be there.
Cannon et al. (Thu,) studied this question.